Andere Kunden interessierten sich auch für
![Penile and Urethral Cancer, an Issue of Urologic Clinics]( "Penile and Urethral Cancer, an Issue of Urologic Clinics")
Penile and Urethral Cancer, an Issue of Urologic Clinics114,99 €![Castration Resistant Prostate Cancer, an Issue of Urologic Clinics]( "Castration Resistant Prostate Cancer, an Issue of Urologic Clinics")
Castration Resistant Prostate Cancer, an Issue of Urologic Clinics113,99 €![Prostate Cancer, an Issue of Urologic Clinics]( "Prostate Cancer, an Issue of Urologic Clinics")
Prostate Cancer, an Issue of Urologic Clinics124,99 €![Evolving Treatment Paradigms in Renal Cancer, an Issue of Urologic Clinics]( "Evolving Treatment Paradigms in Renal Cancer, an Issue of Urologic Clinics")
Evolving Treatment Paradigms in Renal Cancer, an Issue of Urologic Clinics113,99 €![Current Management of Invasive Bladder and Upper Tract Urothelial Cancer, an Issue of Urologic Clinics]( "Current Management of Invasive Bladder and Upper Tract Urothelial Cancer, an Issue of Urologic Clinics")
Current Management of Invasive Bladder and Upper Tract Urothelial Cancer, an Issue of Urologic Clinics124,99 €![Management of High Grade Bladder Cancer: A Multidisciplinary Approach, an Issue of Urologic Clinics]( "Management of High Grade Bladder Cancer: A Multidisciplinary Approach, an Issue of Urologic Clinics")
Management of High Grade Bladder Cancer: A Multidisciplinary Approach, an Issue of Urologic Clinics116,99 €![Lyphadenctomy in Urologic Oncology: Indications, Controversies, and Complications, an Issue of Urologic Clinics]( "Lyphadenctomy in Urologic Oncology: Indications, Controversies, and Complications, an Issue of Urologic Clinics")
Lyphadenctomy in Urologic Oncology: Indications, Controversies, and Complications, an Issue of Urologic Clinics113,99 €
PSA screening remains highly controversial due to several important disadvantages. More PSA is produced with prostatic enlargement and in other benign conditions such as urinary tract infections. False positive tests can then lead to unnecessary diagnostic workup with invasive prostate biopsy. Another major problem with screening programs in general is overdiagnosis of cancers that would not have caused harm during the patient's lifetime. For example, many prostate cancers have a relatively indolent behavior so may not require diagnosis or treatment in a patient with limited life expectancy. All forms of prostate cancer treatment have potential urinary and sexual side effects, so reducing overdiagnosis and overtreatment are critical public health issues. Because screening has many proven benefits but also significant harms, there are widely disparate guidelines on prostate cancer screening from major organizations worldwide. This issue of the Urologic Clinics will provide insights into the many different prostate cancer guidelines and related policy issues.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.